¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º *SkUkqP9z  
s>sIji  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ COS(pfC  
(]'Q!MjGa  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) />fP )56*  
uM0!,~&9|  
1. ICAM-1 _E5%Px5>L  
4XL*e+UfJ  
2. interleukin 12(IL-12) ld1t1'I'  
o/I<)sa  
3. tumor infiltrating lymphocyte '< OB  j  
&]~z-0`$!  
4. TCR/CD3 complex ^RkHdA  
Kb0O auW  
5. hematopoietin receptor family b5YjhRimS  
qE6:`f  
6. individual idiotype(IdI) 8 ?' ]W\)  
hCO*gtA)M  
7. integrin zypZ3g{vz  
9vL`|`Vau  
8. colony-stimulatory factor (CSF) 7Z>u|L($m  
]?,47,[<  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© IS7g{:}=p  
"}D uAs  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? ~Dr/+h:^\  
zW%-Z6%D  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ ?/"@WP9  
MxxYMR  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ\Ja%u"D A  
EF0{o_  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ HKP\`KBC j  
3a#637%  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 6+IOJtj  
8E/$nRfO d  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ [8Ub#<]]  
{a_= 4a  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) =(*Eh=Pw  
(|ga#% iI  
3. immunoglobulin superfamily (IgSF) < PW*vo9v  
? $pGG  
4. selectin ^/R@bp# <  
*%ZfE,bu8<  
5. anti-idiotypic antibody (¦ÁId) ix^:qw;  
0"u*Kn  
6. major histocompatibility complex(MHC)  'm}~  
B/E1nBobC  
7. immunotolerance e kI1j%fO  
*|$s0ga C  
8. biological reponse modifier(BRM) <3HW!7Ad1  
ezwcOYMXK  
9. immune reponse gene (Ir gene) 3`#sXt9C  
ErB6fl  
10. reshaped antibody (or reconstituted antibody) H) q9.Jg  
D8`,PXtV  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© M0c"wi@S_  
nImRU.;P  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ "5XD+qi  
!bH-(K{S6  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? u9mMkzgSkP  
d^]wqnpf  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ X@x: F|/P  
"793R^Tz  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? 9]NsWd^^  
LfOGq%&  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ |V!A!tB  
{!^HG+  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? .RJvu$U2j  
s_`wLQ7e  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ An]*J|nFIY  
pPQ]#v  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ 2Y  6/,W  
)}G HG#D{  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? :Oq!.uO  
7 hnTHL  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ .^JID~<?#  
|C>Yd*E,C  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: VJ_E]}H  
\8Blq5n-O*  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: "]MF =-v  
D*D83z OzN  
ÃâÒßѧ S'E6#   
hC6$>tl  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© p' /$)klt  
d8]6<\g  
1. CD8 n4Q!lJ  
[]LNNO],X  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) m?<C\&)6x  
d6hWmZVC  
3. immunoglobulin fold(Ig fold) (''`Ce  
B*D`KA  
4. cadherin (Ca-dependent cell adhesion moleculers) EWqKd/    
I9>1WT<Yy  
5. idiotype-anti-idiotypic antibody immune network theory ZB ~D_S  
N{Is 2Ia  
6. HLA class II antigen :_Ng`b/  
JN3Oe5yB2@  
7. complementarity-determining region (CDR) p( Qm\g<  
QKOo # 7  
8. perforin(or pore-forming protein ,PFP) lZ_i~;u4@v  
GhpH7% s  
9. high affinity IL-2 receptor PJ #uYM  
-} Z  
10. artificial active immunization t~@TUTbx  
26\1tOj Np  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Y%wF;I1x  
!vett4C* K  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠWb*d`hzQ}  
mH}AVje{ `  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 6Ajiz_~U  
bLNQ%=FjO  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ Wigm`A=,r  
X8*q[@$  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ BH FWig*{  
t0?BU~f  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ ~'T]B{.+J  
`9 $?g| rB  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? *M KVm)Iv  
Vw) \#6FL  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ Ye(0'*-jyc  
e#W@ep|n  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ gk] r:p<O  
>#>YoA@S  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ BJlF@F#  
Q$RP2&  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ %7V?7BE  
w1s#8 :  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© :Eob"WH  
Gzm[4|nO^  
1. immunoglobulin gene rearrangement hr)TC-  
1uD}V7_y"  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) Vxk0oI k`  
*W i(%  
3. flow cytometry(FCM) NGb`f-:jw  
i&?~QQP`  
4. carrier effect 5Pv>`E2^  
OGae]O<  
5. positive selection of T lymphocytes in thymus T`vj6F  
5F0sfX  
6. mouse TH1(Th1) and TH2(Th2) subsets 57r\s 8  
OO\UF6MCU  
7. perforin (pore-forming protein ,PFP) az19-QIcg  
0 J ANj  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) 3 #jPQ[+  
6:h!gY  
9. SH-2(src-homology region 2) wGbD%=  
s[Njk@y,  
10. Ab2¦Â (internal image) f)gA.Rz  
K XR  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© N-vr_4{g  
NEK;'"  ~  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? OZ7MpQ  
McA,  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? w`i3B@w  
"*TnkFTR  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ+fKLCzj  
#mtlgK'  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ ]l& _Pv!!  
gKBcD\F  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ!&! sn"yD  
qzV:N8+,`  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) CQ13fu +|6  
{OB\~$TH  
ÃâÒßѧרҵ£º t0hg!_$bq  
M|76,2u   
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ B \[P/AC  
B&<Z#C:I  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? n?:s /6tP  
z`{Ld9W  
´«È¾²¡Ñ§×¨Òµ£º }JvyjE  
/|hKZTZJdN  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ P>jlFm  
6Pd;I,k  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ {6v+ Dz>  
iQs(Dh=*  
Ïû»¯×¨Òµ£º 9G 9!=J  
 ;-U :t4  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ F&I^bkvh  
Y+j|T`d  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? JAc-5e4  
6uR :/PTG  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ 0FHN  
p \F*Y,4  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© "J7=3$CA  
2 ;U(r: ]  
1. Fas(CD95)/FasL |a/"7B|?\  
*|ubH?71%Y  
2. common chain of cytokine receptor F0]NtKaH  
:J}L| `U9  
3 . TCR/CD3 complex 4GeWo@8h  
)0~zL} )?  
4. negaive selection of thymocytes gQ/-.1Pz$  
1i^!A&  
5. artificial active immune x>Q\j>^  
_}{C?611c  
6. anti-idiotypic 7;0^r#:87#  
/vBOf;L  
7. IgSF .G4 (Ryh  
0,E*9y}  
8. Integrin o-yZ$+V  
z3[ J>  
9. chemokine rAM{<  
<TC\Nb$~  
10. B7/CD28 O#sDZ.EL  
hL+)XJu^J  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© "+~La{ POc  
:Bz*vH  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ iYEhrb  
GNgPf"}K  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ xf_NHKZ)  
[daUtK z  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ ,73J#  
[z'PdYQR/{  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ DZ<q)EpC  
F\^9=}b_i  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ xKi: 2  
jgQn^  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ S8(Y+jgk;a  
ABuK`(f.  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© p2cwW/^V  
7O',X Y  
1. B7/CD28 JPJ&k( P  
x|g>Zd/n  
2. Th1 subset nd_+g2x'  
ixm-wZI  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© `@!4#3H  
#fk#RNt  
4. antibody affinity maturation OE[ | 1?3  
%#kml{I   
5. AP-1 E}LYO:  
0' j/ 9vm  
6. single chain variable fragment£¨ScFv£© ]06orBV  
" iAwD8-  
7. NK cell receptor &m<:&h& b  
}ADdKK-  
8. Zinkernagel-Doherty phenomenon *L7&P46  
xDJ@MW#  
9. Ig fold r I)Y W0  
7-S?\:J  
10. CD40/CD40L +OEqDXR+_  
d rRi<7 i  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© &gGh%:`B  
+h*-9  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ +8p4\l$<`  
T'C^,,if  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ }[2  
f)'m pp^  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ $>if@}u  
f%ThS42  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ ^W8kt  
vU(uu:U9  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ ) oypl+y  
z.d1>w  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ ' v)@K0P  
b9Fd}WZz  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ 8_*31Y   
*h([ai"1-  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© `PoFKtVX M  
'DeI]IeP  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© (D5sJ$&E@\  
pHNo1-k\  
1.Co-stimulators (or co-stimulating molecules) Wxeg(L}E  
H\vd0DD;  
2.NK-kB HP,sNiw  
mG\$W#+j  
3.Immunoglobulin superfamily -|.Izgc  
Ga$J7 R  
4.antigen-presenting cell (APC) ojva~mnFf  
9'" F7>d  
5.death domain -ZVCb@%  
[C-4*qOaa2  
6.CCR and CXCR =tS#t+2S  
VZ3{$0 +  
7.Lectin (or mitogen) m8ApiGG  
hj4mbL  
8.Clusters of differentiation, CD) Mil+> X0  
t@vVE{`  
9.B7 family h<0&|s*a)  
BN>t"9XpW  
10.Cytotoxic T lymphocyte, CTL) f`W)Z$fN5  
'#eY4d<i]n  
11.IL-15 and IL-15 receptor (IL-15R) @,^c?v  
N|5fkx<d^  
12.MHC restriction V] 0T P#  
.+ d.~jHX  
13.Affinity-chromatography eHl)/='  
<y2HzBC  
14.Cyctosprin A, CsA Kt5k_9  
 eQU~A9  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) F%ffnEJg  
ss0`9:z  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© IY"+hHt  
`UD,ne  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 /g)(  
,CxIA^  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ IgyoBfj\d  
PJF1+I.%c#  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ "$#<+H>O  
8|) $;.  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© rbl7-xhC7  
SVn $!t  
ÃâÒßѧרҵ£º w| eVl{~p  
3lsfT-|Wt&  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ eA_]%7+`  
('z:XW96  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ D k<NlH zp  
k+@,m\tE  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ -2B3 xIZJ  
,4HZ-|EOZ  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) xnOd$]  
?0tm{qP  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) ,L=lg,lH^  
{BY(zsl  
1. ADCC(antibody dependent cell-mediated cytotoxicity) L/?jtF:o  
T STkMlCG  
2. »·æß¾úËØ(cyclosporin) j6WDh}#  
YSbe Cyv  
3. KIR(killer cell inhibitory receptor) H=*lj.x  
0TaN#  
4. HLDA(human leucocyte differentiation antigen) ~gdnD4[G  
`96M XP  
5. Interleukin 18(IL-18) dpvEY(Ds  
4_-L1WH  
6. ÕûºÏËØ(integrin) K;ocs?rk/  
pQi|PQq  
7. Fas/FasL 7Ue&y8Yf  
XS$#\UQ  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) ; +1ooeU  
pJ JOy  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) Y;"jsK{$  
%\L{Ud%7  
10. Th1/Th2 + 2w<V0V_  
%~:@}C%A  
11. »ùÒòÒßÃç(DNAÒßÃç) Lvrflx*Q  
\5-Dp9vG  
12. chemokines and chemokine receptor .kTOG'K\e  
.u'MMe>^  
13. ÃâÒßÄÍÊÜ 26p_fKY  
klMpiy  
14. ¹²´Ì¼¤·Ö×Ó TR%8O;  
BMtk/r/  
15. ËÀÍö½á¹¹Óò(death domain) c axO xRo\  
+6x}yc:yd  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) \E'z+0  
$rJgBN   
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? ]Ot= At  
_4T7Vg''  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠuqD|j:~ =k  
\;iOQqv0&  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î E.*gKfL  
bM2x (E\O  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ MEM(uBYKOb  
u08j9) ,4  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå +~|Jn_:A f  
fQ1Dp  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ #M<YNuE#"  
z "z  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) bc NyB$S  
`l6OQdB3W  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ B%`| W@v  
hi4-Z=pl  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ t 1~k+  
XB@i{/6K  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»